172 related articles for article (PubMed ID: 38400112)
1. Lung IL-17A-Producing CD4
Stewart EL; Counoupas C; Quan DH; Wang T; Petrovsky N; Britton WJ; Triccas JA
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400112
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-23 instructs protective multifunctional CD4 T cell responses after immunization with the Mycobacterium tuberculosis subunit vaccine H1 DDA/TDB independently of interleukin-17A.
Ritter K; Behrends J; Erdmann H; Rousseau J; Hölscher A; Volz J; Prinz I; Lindenstrøm T; Hölscher C
J Mol Med (Berl); 2021 Nov; 99(11):1585-1602. PubMed ID: 34351501
[TBL] [Abstract][Full Text] [Related]
3. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
4. Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis.
Counoupas C; Ferrell KC; Ashhurst A; Bhattacharyya ND; Nagalingam G; Stewart EL; Feng CG; Petrovsky N; Britton WJ; Triccas JA
NPJ Vaccines; 2020 Nov; 5(1):105. PubMed ID: 33298977
[TBL] [Abstract][Full Text] [Related]
5. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
6. Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis.
Perdomo C; Zedler U; Kühl AA; Lozza L; Saikali P; Sander LE; Vogelzang A; Kaufmann SH; Kupz A
mBio; 2016 Nov; 7(6):. PubMed ID: 27879332
[TBL] [Abstract][Full Text] [Related]
7. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
8.
Jia Q; Masleša-Galić S; Nava S; Horwitz MA
mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
[TBL] [Abstract][Full Text] [Related]
9. Blockade of IL-10 signaling during bacillus Calmette-Guérin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-γ and IL-17 responses and increases protection to Mycobacterium tuberculosis infection.
Pitt JM; Stavropoulos E; Redford PS; Beebe AM; Bancroft GJ; Young DB; O'Garra A
J Immunol; 2012 Oct; 189(8):4079-87. PubMed ID: 22972927
[TBL] [Abstract][Full Text] [Related]
10. Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis.
Counoupas C; Pinto R; Nagalingam G; Britton WJ; Triccas JA
Vaccine; 2018 May; 36(19):2619-2629. PubMed ID: 29627232
[TBL] [Abstract][Full Text] [Related]
11. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
12. Heterologous Boost Following
Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
Front Immunol; 2018; 9():2439. PubMed ID: 30425711
[TBL] [Abstract][Full Text] [Related]
13. Delta inulin-based adjuvants promote the generation of polyfunctional CD4
Counoupas C; Pinto R; Nagalingam G; Britton WJ; Petrovsky N; Triccas JA
Sci Rep; 2017 Aug; 7(1):8582. PubMed ID: 28819247
[TBL] [Abstract][Full Text] [Related]
14. Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity.
Quan DH; Counoupas C; Nagalingam G; Pinto R; Petrovsky N; Britton WJ; Triccas JA
Vaccine; 2021 Apr; 39(14):1990-1996. PubMed ID: 33714652
[TBL] [Abstract][Full Text] [Related]
15. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.
Todoroff J; Lemaire MM; Fillee C; Jurion F; Renauld JC; Huygen K; Vanbever R
PLoS One; 2013; 8(5):e63344. PubMed ID: 23675482
[TBL] [Abstract][Full Text] [Related]
16. Protection against an aerogenic Mycobacterium tuberculosis infection in BCG-immunized and DNA-vaccinated mice is associated with early type I cytokine responses.
Goter-Robinson C; Derrick SC; Yang AL; Jeon BY; Morris SL
Vaccine; 2006 Apr; 24(17):3522-9. PubMed ID: 16519971
[TBL] [Abstract][Full Text] [Related]
17. Protective Vaccine Efficacy of the Complete Form of PPE39 Protein from Mycobacterium tuberculosis Beijing/K Strain in Mice.
Kim A; Hur YG; Gu S; Cho SN
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877927
[TBL] [Abstract][Full Text] [Related]
18. Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination.
Kang H; Yuan Q; Ma H; Hu ZD; Han DP; Wu K; Lowrie DB; Fan XY
Immunology; 2014 Dec; 143(4):661-9. PubMed ID: 24965530
[TBL] [Abstract][Full Text] [Related]
19. Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1
Bull NC; Stylianou E; Kaveh DA; Pinpathomrat N; Pasricha J; Harrington-Kandt R; Garcia-Pelayo MC; Hogarth PJ; McShane H
Mucosal Immunol; 2019 Mar; 12(2):555-564. PubMed ID: 30446726
[TBL] [Abstract][Full Text] [Related]
20. M.tuberculosis mutants lacking oxygenated mycolates show increased immunogenicity and protective efficacy as compared to M. bovis BCG vaccine in an experimental mouse model.
Hedhli D; Denis O; Barkan D; Daffé M; Glickman MS; Huygen K
PLoS One; 2013; 8(10):e76442. PubMed ID: 24146869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
